Press Releases Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
140.13 ^USD	-2.40%		-6.16%	-19.48%

02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
24/02	Insmed Insider Sold Shares Worth $1,615,257, According to a Recent SEC Filing	MT

Press Releases

05/03	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
19/02	Insmed: Q4 Earnings Snapshot	AQ
19/02	Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update	PR
13/02	Insmed To Present at March 2026 Investor Conferences	PR
05/02	Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026	PR
28/01	Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress	PR
09/01	Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference	PR
02/01	Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference	PR
18/12	Insmed Provides Clinical and Business Update	PR
04/12	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
20/11	Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment	AQ
19/11	Insmed Incorporated - European Commission Approves BRINSUPRI as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	AQ
18/11	European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	PR
13/11	Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good	PR
05/11	Insmed To Present at November and December 2025 Investor Conferences	PR
30/25/30	Insmed: Q3 Earnings Snapshot	AQ
30/25/30	Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update	PR
24/25/24	Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List	PR
17/25/17	CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis	PR
16/25/16	Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025	PR
15/25/15	Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025	PR
22/25/22	Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025	PR
05/25/05	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
21/25/21	Insmed To Present at September Investor Conferences	PR
20/25/20	Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)	AQ